NCT04495140View on ClinicalTrials.gov

Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 22, 2020

Primary Completion Date

October 15, 2020

Study Completion Date

October 15, 2020

Conditions
Healthy Volunteer
Interventions
DRUG

[14C]PF-06882961, 50 mg

A single oral dose of \[14C\]PF-06882961, will be administered as a liquid formulation.

DRUG

PF-06882961, 50 mg and [14C]PF-06882961, 100 ug

A single, oral, unlabeled dose of PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-06882961 will be administered via intravenous infusion.

Trial Locations (2)

9728 NZ

PRA Health Sciences, Groningen

3584 BL

PRA Health Sciences Utrecht, Utrecht

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04495140 - Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961 | Biotech Hunter | Biotech Hunter